The H2-receptor antagonist era in duodenal ulcer disease
- PMID: 1364125
- PMCID: PMC2589764
The H2-receptor antagonist era in duodenal ulcer disease
Abstract
This paper reviews the remarkable impact of H2-receptor antagonists on duodenal ulcer management. The development and the scientific rationale of these agents are presented, and efficacy and safety aspects in the short- and long-term treatment of duodenal ulcer disease discussed. Attention is focused on the possible role of "acid rebound" in ulcer relapse following the withdrawal of therapy and on the clinical relevance of prolonged suppression of acid secretion in patients on long-term therapy.
Similar articles
-
Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.Yale J Biol Med. 1996 May-Jun;69(3):211-24. Yale J Biol Med. 1996. PMID: 9165690 Free PMC article. Review.
-
Histamine H2-receptor antagonists.Adv Intern Med. 1978;23:1-24. Adv Intern Med. 1978. PMID: 24327 Review.
-
A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.Nurse Pract. 1989 Feb;14(2):41-2. Nurse Pract. 1989. PMID: 2564655
-
Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer.Clin Gastroenterol. 1984 May;13(2):501-41. Clin Gastroenterol. 1984. PMID: 6146417 Review. No abstract available.
-
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.Clin Ther. 1993;15 Suppl B:14-21. Clin Ther. 1993. PMID: 7911399 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources